Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
Key Clinical Message Temsirolimus did not demonstrate an efficacy advantage compared with sorafenib as second‐line therapy in patients with metastatic renal cell carcinoma (mRCC). Only a few patients achieved complete responses, and the median progression‐free survival rate remains short. We report...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Wiley
2017-12-01
|
| Sraith: | Clinical Case Reports |
| Ábhair: | |
| Rochtain ar líne: | https://doi.org/10.1002/ccr3.1181 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|